HIKAL Hikal Q2 FY26 results (Jul–Sep 2025) and concall
Hikal reported a challenging Q2 FY26, with consolidated revenue of ₹319 crores and a low EBITDA margin of 2.6%, primarily due to a significant deferral of pharmaceutical sales to October 2025 following US FDA regulatory actions. Both pharma and crop protection segments recorded negative EBIT margins. Despite the short-term headwinds, management expressed confidence in a strong recovery in H2 FY26, driven by new product commercialization, increased capacity utilization, and ongoing remediation efforts for the FDA observations, with a re-inspection anticipated in early to mid-2026.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 29.7%, net profit down 290.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 453 | 448 | 552 | 380 | 319 −30% |
| EBITDA | 75 | 72 | 123 | 25 | 7 −90% |
| Net profit | 18 | 17 | 50 | -22 | -35 −291% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
